01
Cash & equivalents increased 61.5%
Cash & equivalents changed +61.5% from the comparable as-filed period.
$36.8M→$59.4MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAcumen Pharmaceuticals, Inc.'s latest supported as-filed period reports interest income of $3.1M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +61.5% from the comparable as-filed period.
Debt changed -60.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed +20.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ABOS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-056199SEC ↗8-KAug 12, 2026Period Aug 12, 20260001628280-26-055940SEC ↗4Jun 17, 2026Period Jun 15, 20260001628280-26-043987SEC ↗8-KJun 16, 2026Period Jun 12, 20260001628280-26-043416SEC ↗4Jun 10, 2026Period Jun 9, 20260001628280-26-042280SEC ↗4Jun 5, 2026Period Jun 3, 20260001231919-26-000604SEC ↗4Jun 5, 2026Period Jun 3, 20260001628280-26-041281SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 17, 2026Filed Jun 17, 2026 | Porter DerrellDirector | Option ExerciseDirect | 13,040 | $1 | $13,953 | Form 4 ↗ |
| Jun 17, 2026Filed Jun 17, 2026 | Porter DerrellDirector | Open Market SaleDirect | 13,040 | $2 | $30,318 | Form 4 ↗ |
| Jun 17, 2026Filed Jun 17, 2026 | Porter DerrellDirector | Option ExerciseDirect | 13,040 | $0 | $0 | Form 4 ↗ |
| Jun 16, 2026Filed Jun 17, 2026 | Porter DerrellDirector | Open Market SaleDirect | 12,800 | $2 | $29,773 | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +22.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed -25.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +1.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-041276| Porter DerrellDirector |
| Option ExerciseDirect |
| 6,460 |
| $1 |
| $6,912 |
| Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Porter DerrellDirector | Option ExerciseDirect | 6,460 | $0 | $0 | Form 4 ↗ |
| Jun 15, 2026Filed Jun 17, 2026 | Porter DerrellDirector | Open Market SaleDirect | 6,460 | $2 | $15,149 | Form 4 ↗ |